Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 16/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459458 | 1.00 | CCR5 (0.40) | CCR5HTR1AHTR7ALDH1A1 | |
| SCHEMBL5466460 | 0.94 | SIGMAR1 (0.41) | CCR5HTR1AHTR7 | |
| SCHEMBL5449623 | 0.92 | CCR5 (0.46) | CCR5HTR1AHTR7 | |
| SCHEMBL5456309 | 0.89 | DRD2 (0.37) | CCR5HTR7 | |
| SCHEMBL5454541 | 0.81 | CCR5 (0.47) | CCR5 | |
| SCHEMBL5460748 | 0.81 | CCR5 (0.47) | CCR5 | |
| SCHEMBL5459461 | 0.78 | CCR5 (0.41) | CCR5HTR1AHTR7ALDH1A1 | |
| SCHEMBL5453882 | 0.78 | CCR5 (0.41) | CCR5ALDH1A1 | |
| SCHEMBL5459464 | 0.78 | CCR5 (0.41) | CCR5ALDH1A1 | |
| SCHEMBL5453879 | 0.78 | CCR5 (0.41) | CCR5HTR1AHTR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | claimed |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | CHAMBERS MARK S | 2007-05-24 | — | — | US | disclosed |
| US-7153868-B2 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. | 2006-12-26 | — | — | US | disclosed |
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | KCNH3, KCNH2, KCNK3 | CCR5 710/4885HTR1A 461/4885HTR7 867/4885 |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | TACR2, KCNK3, KCNH3 | CCR5 1040/4885HTR1A 342/4885HTR7 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.